NCT01033149终止3 期
N-acetylcysteine in the Treatment of Bulimia Nervosa
Lindner Center of HOPE1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- The primary outcome measure will be the weekly frequency of binge-purge episodes.
研究概览
简要总结
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of N-acetylcysteine (NAC) in the treatment on bulimia nervosa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women, between the ages of 18 and
- •The patient population is expected to be predominantly made up of women based on previous research.
- •Patients will meet DSM-IV-TR criteria for BN for at least the last 6 months. These criteria are as follows:
- •A. Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:
- •Eating, in a fixed period of time, an amount of food that is definitely larger than most people would eat under similar circumstances.
- •A sense of lack of control over eating during the episode B. Recurrent inappropriate compensatory behavior to prevent weight gain, such as: self-induced vomiting; misuse of laxatives; diuretics; or other medications; fasting; excessive exercise.
- •C. Binge-purge episodes occur at least two times a week in the last 3 months D. Self- evaluation in unduly influenced by body shape and weight E. The disturbance does not occur exclusively during episodes of anorexia nervosa.
- •Capacity to consent to the study and comply with study procedures.
排除标准
- •Criteria for exclusion from this study will be any of the following:
- •Have current body mass index (BMI) < 20kg/m
- •Women who are pregnant or lactating and women of childbearing potential who are not taking adequate contraceptive measures.
- •Subjects who are displaying clinically significant suicidality or homicidality.
- •A current or recent (within 6 months of the start of NAC) DSM-IV-TR diagnosis of substance abuse or dependence.
- •History of a personality disorder (eg, schizotypal, borderline, or antisocial) which might interfere with assessment or compliance with study procedures
- •Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, assessment, or treatment of BN. Patients should be biochemically euthyroid prior to entering the study.
- •DSM-IV-TR Anorexia nervosa
- •Serum potassium of ≤ 0.3mmol/L
- •Myocardial infarction within six months
- •Subjects taking more than 200 /µg of selenium per day, or 500 IU of Vitamin E /day
- •Subjects with known or suspected clinically relevant systemic medical disorder, including asthma, bronchospasm, or respiratory insufficiency.
- •Subjects who had recently used medications (<14 days) felt to be hazardous if taken with NAC (e.g. carbamazepine, nitroglycerin).
- •Subjects previously enrolled in this study; subjects who have previously been treated with NAC; subjects who have received an experimental drug or have used an experimental device within 30 days.
- •Subjects who are taking psychotropic medications will be allowed into the study as long as the dose of medication had been stable for 3 months before study inclusion and there are no plans to modify the dose during the study duration. Similarly, subjects evolved in psychotherapy for BN will be allowed to participate if attendance had been ongoing for at least 3 months before study entry. Subjects who changed doses of medication or started new therapy will be discontinued from the study.
研究组 & 干预措施
N-acetylcysteine
Other
open label N-acetylcysteine, flexible dose
干预措施: N-acetylcysteine (Drug)
结局指标
主要结局
The primary outcome measure will be the weekly frequency of binge-purge episodes.
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
N-acetylcysteine in Bulimia NervosaNACNCT01131572Lindner Center of HOPE11
已完成
2 期
N-acetylcysteine for Tobacco Use DisorderNicotine DependenceSmokingNCT02737358Medical University of South Carolina114
已完成
不适用
The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth SyndromeBurning Mouth SyndromeNCT05309070University of Zagreb80
已完成
2 期
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine DependenceMethamphetamine DependenceNCT00332605University of Chicago45
已完成
2 期
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological GamblersGamblingTobacco Use DisorderNCT00967005University of Chicago28